PDCD1 and cancer: Moreover, response to PD-1 inhibitors differs between inflamed and non-inflamed tumors [32] and cancer stemness and intra-tumoral heterogeneity may have a greater impact on immune response and may better predict immunotherapy outcomes than TMB [33].